Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Knee joint sagittal plane movement in cerebral palsy: a comparative study of 2-dimensional markerless video and 3-dimensional gait analysis.

Pantzar-Castilla E, Cereatti A, Figari G, Valeri N, Paolini G, Della Croce U, Magnuson A, Riad J.

Acta Orthop. 2018 Dec;89(6):656-661. doi: 10.1080/17453674.2018.1525195.

2.

LONG-NONCODING RNAs in gastroesophageal cancers.

Fanelli GN, Gasparini P, Coati I, Cui R, Pakula H, Chowdhury B, Valeri N, Loupakis F, Kupcinskas J, Cappellesso R, Fassan M.

Noncoding RNA Res. 2018 Nov 1;3(4):195-212. doi: 10.1016/j.ncrna.2018.10.001. eCollection 2018 Dec. Review.

3.

A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.

Smyth EC, Nyamundanda G, Cunningham D, Fontana E, Ragulan C, Tan IB, Lin SJ, Wotherspoon A, Nankivell M, Fassan M, Lampis A, Hahne JC, Davies AR, Lagergren J, Gossage JA, Maisey N, Green M, Zylstra JL, Allum WH, Langley RE, Tan P, Valeri N, Sadanandam A.

Ann Oncol. 2018 Dec 1;29(12):2356-2362. doi: 10.1093/annonc/mdy407.

4.

miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis.

Fassan M, Cui R, Gasparini P, Mescoli C, Guzzardo V, Vicentini C, Munari G, Loupakis F, Lonardi S, Braconi C, Scarpa M, D'Angelo E, Pucciarelli S, Angriman I, Agostini M, D'Incá R, Farinati F, Gafà R, Lanza G, Frankel WL, Croce CM, Valeri N, Rugge M.

Transl Oncol. 2019 Feb;12(2):282-291. doi: 10.1016/j.tranon.2018.10.013. Epub 2018 Nov 16.

5.

Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications.

Salati M, Valeri N, Spallanzani A, Braconi C, Cascinu S.

Eur J Surg Oncol. 2018 Nov 10. pii: S0748-7983(18)31997-8. doi: 10.1016/j.ejso.2018.11.006. [Epub ahead of print]

PMID:
30448343
6.

Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.

Khan K, Rane JK, Cunningham D, Rao S, Watkins D, Starling N, Kalaitzaki E, Forster M, Braconi C, Valeri N, Gerlinger M, Chau I.

Clin Colorectal Cancer. 2018 Sep 29. pii: S1533-0028(18)30219-6. doi: 10.1016/j.clcc.2018.09.010. [Epub ahead of print]

PMID:
30404764
7.

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.

Wagner S, Vlachogiannis G, De Haven Brandon A, Valenti M, Box G, Jenkins L, Mancusi C, Self A, Manodoro F, Assiotis I, Robinson P, Chauhan R, Rust AG, Matthews N, Eason K, Khan K, Starling N, Cunningham D, Sadanandam A, Isacke CM, Kirkin V, Valeri N, Whittaker SR.

Oncogene. 2018 Oct 23. doi: 10.1038/s41388-018-0554-z. [Epub ahead of print]

PMID:
30353166
8.

Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases.

Fassan M, Vianello L, Sacchi D, Fanelli GN, Munari G, Scarpa M, Cappellesso R, Loupakis F, Lanza C, Salmaso R, Mescoli C, Valeri N, Agostini M, D'Angelo E, Lonardi S, Pucciarelli S, Veronese N, Luchini C, Rugge M.

Cancer Cell Int. 2018 Sep 6;18:131. doi: 10.1186/s12935-018-0634-8. eCollection 2018.

9.

Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches.

Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N.

Cell Mol Life Sci. 2018 Nov;75(22):4151-4162. doi: 10.1007/s00018-018-2906-9. Epub 2018 Sep 1. Review.

10.

Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.

Khan KH, Cunningham D, Werner B, Vlachogiannis G, Spiteri I, Heide T, Mateos JF, Vatsiou A, Lampis A, Damavandi MD, Lote H, Huntingford IS, Hedayat S, Chau I, Tunariu N, Mentrasti G, Trevisani F, Rao S, Anandappa G, Watkins D, Starling N, Thomas J, Peckitt C, Khan N, Rugge M, Begum R, Hezelova B, Bryant A, Jones T, Proszek P, Fassan M, Hahne JC, Hubank M, Braconi C, Sottoriva A, Valeri N.

Cancer Discov. 2018 Oct;8(10):1270-1285. doi: 10.1158/2159-8290.CD-17-0891. Epub 2018 Aug 30.

PMID:
30166348
11.

HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer.

Lote H, Valeri N, Chau I.

World J Gastrointest Oncol. 2018 Jul 15;10(7):159-171. doi: 10.4251/wjgo.v10.i7.159. Review.

12.

Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.

Mensah AA, Cascione L, Gaudio E, Tarantelli C, Bomben R, Bernasconi E, Zito D, Lampis A, Hahne JC, Rinaldi A, Stathis A, Zucca E, Kwee I, Gattei V, Valeri N, Riveiro ME, Bertoni F.

Haematologica. 2018 Aug 3. pii: haematol.2018.191684. doi: 10.3324/haematol.2018.191684. [Epub ahead of print]

13.

Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.

Sundar R, Miranda S, Rodrigues DN, Chénard-Poirier M, Dolling D, Clarke M, Figueiredo I, Bertan C, Yuan W, Ferreira A, Chistova R, Boysen G, Perez DR, Tunariu N, Mateo J, Wotherspoon A, Chau I, Cunningham D, Valeri N, Carreira S, de Bono J.

Clin Colorectal Cancer. 2018 Dec;17(4):280-284. doi: 10.1016/j.clcc.2018.05.011. Epub 2018 Jun 8.

14.

MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.

Ghidini M, Hahne JC, Frizziero M, Tomasello G, Trevisani F, Lampis A, Passalacqua R, Valeri N.

Target Oncol. 2018 Aug;13(4):423-436. doi: 10.1007/s11523-018-0580-3.

PMID:
30006826
15.

Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors.

Hahne JC, Valeri N.

Front Oncol. 2018 Jun 18;8:226. doi: 10.3389/fonc.2018.00226. eCollection 2018. Review.

16.

Translational research and application of basic biology to clinical trial development in GI cancers.

Smyth E, Khan K, Valeri N.

Ann Transl Med. 2018 May;6(9):164. doi: 10.21037/atm.2018.05.05. Review.

17.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri N.

Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774.

18.

Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial.

Davarzani N, Hutchins GGA, West NP, Hewitt LC, Nankivell M, Cunningham D, Allum WH, Smyth E, Valeri N, Langley RE, Grabsch HI.

Histopathology. 2018 Jun;72(7):1180-1188. doi: 10.1111/his.13491. Epub 2018 Mar 25.

19.

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.

Sclafani F, Chau I, Cunningham D, Hahne JC, Vlachogiannis G, Eltahir Z, Lampis A, Braconi C, Kalaitzaki E, De Castro DG, Wotherspoon A, Capdevila J, Glimelius B, Tarazona N, Begum R, Lote H, Hulkki Wilson S, Mentrasti G, Brown G, Tait D, Oates J, Valeri N.

Sci Rep. 2018 Jan 23;8(1):1445. doi: 10.1038/s41598-018-19212-5.

20.

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.

Moorcraft SY, Gonzalez de Castro D, Cunningham D, Jones T, Walker BA, Peckitt C, Yuan LC, Frampton M, Begum R, Eltahir Z, Wotherspoon A, Teixeira Mendes LS, Hulkki Wilson S, Gillbanks A, Baratelli C, Fotiadis N, Patel A, Braconi C, Valeri N, Gerlinger M, Rao S, Watkins D, Chau I, Starling N.

Ann Oncol. 2018 Jan 1;29(1):230-236. doi: 10.1093/annonc/mdx631.

PMID:
29361134
21.

First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study.

Tomasello G, Valeri N, Ghidini M, Smyth EC, Liguigli W, Toppo L, Mattioli R, Curti A, Hahne JC, Negri FM, Panni S, Ratti M, Lazzarelli S, Gerevini F, Colombi C, Panni A, Rovatti M, Treccani L, Martinotti M, Passalacqua R.

Oncotarget. 2017 Dec 4;8(67):111795-111806. doi: 10.18632/oncotarget.22909. eCollection 2017 Dec 19.

22.

MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.

Lampis A, Carotenuto P, Vlachogiannis G, Cascione L, Hedayat S, Burke R, Clarke P, Bosma E, Simbolo M, Scarpa A, Yu S, Cole R, Smyth E, Mateos JF, Begum R, Hezelova B, Eltahir Z, Wotherspoon A, Fotiadis N, Bali MA, Nepal C, Khan K, Stubbs M, Hahne JC, Gasparini P, Guzzardo V, Croce CM, Eccles S, Fassan M, Cunningham D, Andersen JB, Workman P, Valeri N, Braconi C.

Gastroenterology. 2018 Mar;154(4):1066-1079.e5. doi: 10.1053/j.gastro.2017.10.043. Epub 2017 Nov 4.

23.

Characterisation of the immune-related transcriptome in resected biliary tract cancers.

Ghidini M, Cascione L, Carotenuto P, Lampis A, Trevisani F, Previdi MC, Hahne JC, Said-Huntingford I, Raj M, Zerbi A, Mescoli C, Cillo U, Rugge M, Roncalli M, Torzilli G, Rimassa L, Santoro A, Valeri N, Fassan M, Braconi C.

Eur J Cancer. 2017 Nov;86:158-165. doi: 10.1016/j.ejca.2017.09.005. Epub 2017 Oct 6.

24.

Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.

Smyth E, Zhang S, Cunningham D, Wotherspoon A, Soong R, Peckitt C, Valeri N, Fassan M, Rugge M, Okines A, Allum W, Stenning S, Nankivell M, Langley R, Tan P.

Clin Cancer Res. 2017 Dec 15;23(24):7543-7549. doi: 10.1158/1078-0432.CCR-16-3142. Epub 2017 Oct 2.

25.

A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.

Battersby NJ, Dattani M, Rao S, Cunningham D, Tait D, Adams R, Moran BJ, Khakoo S, Tekkis P, Rasheed S, Mirnezami A, Quirke P, West NP, Nagtegaal I, Chong I, Sadanandam A, Valeri N, Thomas K, Frost M, Brown G.

Trials. 2017 Aug 29;18(1):394. doi: 10.1186/s13063-017-2085-2.

26.

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.

Khan K, Rata M, Cunningham D, Koh DM, Tunariu N, Hahne JC, Vlachogiannis G, Hedayat S, Marchetti S, Lampis A, Damavandi MD, Lote H, Rana I, Williams A, Eccles SA, Fontana E, Collins D, Eltahir Z, Rao S, Watkins D, Starling N, Thomas J, Kalaitzaki E, Fotiadis N, Begum R, Bali M, Rugge M, Temple E, Fassan M, Chau I, Braconi C, Valeri N.

Gut. 2018 Aug;67(8):1484-1492. doi: 10.1136/gutjnl-2017-314178. Epub 2017 Aug 8.

27.

Early miR-223 Upregulation in Gastroesophageal Carcinogenesis.

Fassan M, Saraggi D, Balsamo L, Realdon S, Scarpa M, Castoro C, Coati I, Salmaso R, Farinati F, Guzzardo V, Arcidiacono D, Munari G, Gasparini P, Veronese N, Luchini C, Valeri N, Rugge M.

Am J Clin Pathol. 2017 Mar 1;147(3):301-308. doi: 10.1093/ajcp/aqx004.

PMID:
28395057
28.

Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.

Lote H, Spiteri I, Ermini L, Vatsiou A, Roy A, McDonald A, Maka N, Balsitis M, Bose N, Simbolo M, Mafficini A, Lampis A, Hahne JC, Trevisani F, Eltahir Z, Mentrasti G, Findlay C, Kalkman EAJ, Punta M, Werner B, Lise S, Aktipis A, Maley C, Greaves M, Braconi C, White J, Fassan M, Scarpa A, Sottoriva A, Valeri N.

Ann Oncol. 2017 Jun 1;28(6):1243-1249. doi: 10.1093/annonc/mdx074.

29.

Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.

Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, Fassan M, Rugge M, Valeri N, Okines A, Hewish M, Allum W, Stenning S, Nankivell M, Langley R, Cunningham D.

JAMA Oncol. 2017 Sep 1;3(9):1197-1203. doi: 10.1001/jamaoncol.2016.6762.

30.

The molecular landscape of colitis-associated carcinogenesis.

Saraggi D, Fassan M, Mescoli C, Scarpa M, Valeri N, Michielan A, D'Incá R, Rugge M.

Dig Liver Dis. 2017 Apr;49(4):326-330. doi: 10.1016/j.dld.2016.12.011. Epub 2016 Dec 21. Review.

PMID:
28089111
31.

Combining Molecularly Targeted Agents: Is More Always Better?

Sundar R, Valeri N, Harrington KJ, Yap TA.

Clin Cancer Res. 2017 Mar 1;23(5):1123-1125. doi: 10.1158/1078-0432.CCR-16-2399. Epub 2016 Nov 10.

32.

MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma.

Trevisani F, Ghidini M, Larcher A, Lampis A, Lote H, Manunta P, Alibrandi MT, Zagato L, Citterio L, Dell'Antonio G, Carenzi C, Capasso G, Rugge M, Rigotti P, Bertini R, Cascione L, Briganti A, Salonia A, Benigni F, Braconi C, Fassan M, Hahne JC, Montorsi F, Valeri N.

Br J Cancer. 2016 Nov 22;115(11):1343-1350. doi: 10.1038/bjc.2016.329. Epub 2016 Nov 1.

33.

Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.

Carotenuto P, Fassan M, Pandolfo R, Lampis A, Vicentini C, Cascione L, Paulus-Hock V, Boulter L, Guest R, Quagliata L, Hahne JC, Ridgway R, Jamieson T, Athineos D, Veronese A, Visone R, Murgia C, Ferrari G, Guzzardo V, Evans TRJ, MacLeod M, Feng GJ, Dale T, Negrini M, Forbes SJ, Terracciano L, Scarpa A, Patel T, Valeri N, Workman P, Sansom O, Braconi C.

Gut. 2017 Jul;66(7):1268-1277. doi: 10.1136/gutjnl-2016-312278. Epub 2016 Sep 12.

34.

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.

Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghidini M, Lote H, Zito D, Tabernero J, Glimelius B, Cervantes A, Begum R, De Castro DG, Wilson SH, Peckitt C, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Braconi C, Valeri N.

Carcinogenesis. 2016 Sep;37(9):852-7. doi: 10.1093/carcin/bgw073. Epub 2016 Jul 5.

35.

Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.

Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M, Langley R, Ghidini M, Braconi C, Wotherspoon A, Grabsch HI, Valeri N.

J Clin Oncol. 2016 Aug 10;34(23):2721-7. doi: 10.1200/JCO.2015.65.7692. Epub 2016 Jun 13.

36.

Let-7c down-regulation in Helicobacter pylori-related gastric carcinogenesis.

Fassan M, Saraggi D, Balsamo L, Cascione L, Castoro C, Coati I, De Bernard M, Farinati F, Guzzardo V, Valeri N, Zambon CF, Rugge M.

Oncotarget. 2016 Jan 26;7(4):4915-24. doi: 10.18632/oncotarget.6642.

37.

From Barrett metaplasia to esophageal adenocarcinoma: the molecular background.

Saraggi D, Fassan M, Bornschein J, Farinati F, Realdon S, Valeri N, Rugge M.

Histol Histopathol. 2016 Jan;31(1):25-32. doi: 10:14670/HH-11-659. Epub 2015 Sep 3. Review.

PMID:
26334343
38.

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N.

Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10.

39.

An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality.

Slattery ML, Herrick JS, Mullany LE, Valeri N, Stevens J, Caan BJ, Samowitz W, Wolff RK.

Int J Cancer. 2015 Jul 15;137(2):428-38. doi: 10.1002/ijc.29384. Epub 2014 Dec 16.

40.

Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis.

Fassan M, Dall'Olmo L, Galasso M, Braconi C, Pizzi M, Realdon S, Volinia S, Valeri N, Gasparini P, Baffa R, Souza RF, Vicentini C, D'Angelo E, Bornschein J, Nuovo GJ, Zaninotto G, Croce CM, Rugge M.

Oncotarget. 2014 Aug 30;5(16):7162-71.

41.

An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer.

Ryan BM, Wolff RK, Valeri N, Khan M, Robinson D, Paone A, Bowman ED, Lundgreen A, Caan B, Potter J, Brown D, Croce C, Slattery ML, Harris CC.

Cancer Epidemiol. 2014 Oct;38(5):583-90. doi: 10.1016/j.canep.2014.07.003. Epub 2014 Aug 15.

PMID:
25132422
42.

c-Src drives intestinal regeneration and transformation.

Cordero JB, Ridgway RA, Valeri N, Nixon C, Frame MC, Muller WJ, Vidal M, Sansom OJ.

EMBO J. 2014 Jul 1;33(13):1474-91. doi: 10.1002/embj.201387454. Epub 2014 Apr 30.

43.

MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer.

Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat F, Paone A, Cascione L, Sumani KM, Veronese A, Fabbri M, Carasi S, Alder H, Lanza G, Gafa' R, Moyer MP, Ridgway RA, Cordero J, Nuovo GJ, Frankel WL, Rugge M, Fassan M, Groden J, Vogt PK, Karin M, Sansom OJ, Croce CM.

Cancer Cell. 2014 Apr 14;25(4):469-83. doi: 10.1016/j.ccr.2014.03.006.

44.

An investigation into the mechanical and aesthetic properties of new generation coated nickel-titanium wires in the as-received state and after clinical use.

Bradley TG, Berzins DW, Valeri N, Pruszynski J, Eliades T, Katsaros C.

Eur J Orthod. 2014 Jun;36(3):290-6. doi: 10.1093/ejo/cjt048. Epub 2013 Jul 19.

45.

Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples.

Nuovo GJ, Garofalo M, Valeri N, Roulstone V, Volinia S, Cohn DE, Phelps M, Harrington KJ, Vile R, Melcher A, Galanis E, Sehl S, Adair R, Scott K, Rose A, Toogood G, Coffey MC.

Mod Pathol. 2012 Oct;25(10):1333-44. doi: 10.1038/modpathol.2012.95. Epub 2012 Jun 15.

46.

rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer.

Ryan BM, McClary AC, Valeri N, Robinson D, Paone A, Bowman ED, Robles AI, Croce C, Harris CC.

PLoS One. 2012;7(5):e36306. doi: 10.1371/journal.pone.0036306. Epub 2012 May 11.

47.

MicroRNAs in the pathogenesis of cancer.

Lovat F, Valeri N, Croce CM.

Semin Oncol. 2011 Dec;38(6):724-33. doi: 10.1053/j.seminoncol.2011.08.006. Review.

PMID:
22082758
48.

Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.

Voltan R, di Iasio MG, Bosco R, Valeri N, Pekarski Y, Tiribelli M, Secchiero P, Zauli G.

Clin Cancer Res. 2011 Sep 1;17(17):5649-55. doi: 10.1158/1078-0432.CCR-11-1064. Epub 2011 Jul 13.

49.

microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer.

Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, Negrini M, Miotto E, Croce CM, Patel T.

Oncogene. 2011 Nov 24;30(47):4750-6. doi: 10.1038/onc.2011.193. Epub 2011 May 30.

50.

Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.

Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell'Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM.

JAMA. 2011 Jan 5;305(1):59-67. doi: 10.1001/jama.2010.1919.

Supplemental Content

Loading ...
Support Center